Morgan Stanley Downgrades Bolt Biotherapeutics, Inc. (BOLT) to Equalweight
Tweet
Share
E-mailGet Alerts BOLT Hot Sheet
Price: $3.35 +4.36%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison downgraded Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) from Overweight to Equalweight with a price target of $11.00.
For an analyst ratings summary and ratings history on Bolt Biotherapeutics, Inc. click here. For more ratings news on Bolt Biotherapeutics, Inc. click here.
Shares of Bolt Biotherapeutics, Inc. closed at $4.20 yesterday.
You May Also Be Interested In
- Bolt Biotherapeutics (BOLT) Misses Q2 EPS by 124c
- Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
